Core Viewpoint - Xiamen Ade Biological Pharmaceutical Technology Co., Ltd. has initiated a share repurchase plan aimed at reducing its registered capital, with a total repurchase fund ranging from 100 million to 200 million yuan [1][2]. Repurchase Plan Overview - The share repurchase plan was approved at the company's first extraordinary general meeting of shareholders on November 10, 2025, with a repurchase period of 12 months, ending on November 9, 2026 [2]. - The funds for the repurchase will come from the company's own and/or self-raised funds, with the explicit purpose of "cancellation and reduction of registered capital" [2]. Creditor Declaration Arrangement - The company has notified all creditors regarding the share repurchase and capital reduction, allowing them to declare their claims within 45 days from November 10, 2025 [3]. - Creditors who fail to declare their claims within the specified period will still retain the validity of their claims, and the company will continue to fulfill its obligations according to the original debt documents [3]. Declaration Material Requirements - Creditors must provide specific documentation to declare their claims, including contracts or agreements proving the existence of the debt relationship, and identification documents for both corporate and individual creditors [4]. Subsequent Arrangements - The company will decide on the timing, price, and quantity of the repurchase based on market conditions and will disclose the progress of the repurchase in accordance with regulatory requirements [5]. - The implementation of the share repurchase plan is expected to positively impact the company's stock price and long-term development by optimizing its capital structure [5].

证券代码：300685 证券简称：艾德生物 公告编号:2025-056 1、申报时间：2025年11月10日起45日内（工作日9:00-11:30,13:30-16:30） 关于回购股份用于注销并减少注册资本 暨通知债权人的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、通知债权人的原由 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"） 于2025年11月10日召开2025年第一次临时股东大会，审议通过了《关于以集中竞 价交易方式回购公司股份的议案》。公司使用自有资金和/或自筹资金，以集中 竞价方式回购股份用于注销并减少公司注册资本；回购资金总额为不低于人民币 10,000万元且不超过人民币20,000万元，具体回购资金金额以回购实施完成时实 际回购的金额为准；回购股份的实施期限为自公司股东大会审议通过本次回购方 案之日起12个月内。具体内容详见公司于2025年11月10日及10月25日刊登在巨潮 资讯网的相关公告。公司将根据股东大会的授权，在回购期限内根据市场情况择 机做出回购决策并予以实施。 二、债权申报相关事项 根据《公司法》等相关 ...

证券代码：300685 证券简称：艾德生物 公告编号：2025-055 厦门艾德生物医药科技股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东大会无变更、否决提案的情况； 2.本次股东大会未涉及变更以往股东大会决议； 3.本次股东大会以现场投票和网络投票相结合的方式召开。 一、会议召开和出席情况 1、召集人：公司董事会 2、召开方式：现场投票与网络投票相结合的方式 3、召开时间： （1）现场会议时间：2025 年 11 月 10 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 10 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为 2025 年 11 月 10 日 9:15 至 15:00 的任意时间。 4、股权登记日：2025年11月03日 由于公司董事长LI-MOU ZHENG先生因公外出不能主持本次会议，由半数 以上董事共同推举董事阮力先生主持本次会 ...

法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9、11、12 层 电话：021-20511000 传真：021-20511999 邮政编码：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于厦门艾德生物医药科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 上海市锦天城律师事务所 关于厦门艾德生物医药科技股份有限公司 2025年第一次临时股东大会的 按照律师行业公认的业务标准、道德规范和勤勉尽责精神，本所律师对本次 股东会的相关资料和事实进行了核查和验证，现发表法律意见如下： 一、本次股东会的召集、召开程序 1、本次股东会的召集 2025 年 10 月 24 日，公司召开第四届董事会第九次会议，审议通过《关于 召开 2025 年第一次临时股东大会的议案》，决定召开本次股东会。2025 年 10 1 上海市锦天城律师事务所 法律意见书 致：厦门艾德生物医药科技股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受厦门艾德生物医药科技 股份有限公司（以下简称"公司"）的委托，指派本所律师出席了公司 2025 年 第一次临时股东大会（以下简称"本次股 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：300685 证券简称：艾德生物 公告编号：2025-054 厦门艾德生物医药科技股份有限公司 关于回购股份事项前十名股东及前十名无限售条件股东 持股情况的公告 | 序号 | 账户名称 | 持股数量 （股） | 占无限售条件 流通股股本比 | | --- | --- | --- | --- | | | | | 例（%） | | 1 | 前瞻投资（香港）有限公司 | 87,701,616 | 22.51 | | 2 | 香港中央结算有限公司 | 31,394,756 | 8.06 | | 3 | 厦门科英投资合伙企业（有限合伙） | 15,940,946 | 4.09 | | 4 | 宁波屹祥自有资金投资合伙企业（有限合伙） | 8,731,000 | 2.24 | | 5 | 中国银行股份有限公司－华宝中证医疗交易型开放式 指数证券投资基金 | 7,964,200 | 2.04 | | 6 | 厦门市海沧区润鼎盛投资合伙企业（普通合伙） | 4,098,726 | 1.05 | | 7 | 宋宁 | 3 ...

Policy Developments - The National Health Commission and five other departments launched a one-year special campaign against illegal ambulances, targeting both registered "ambulance" vehicles and unregistered "black ambulances" [2] - The campaign includes comprehensive inspections, management principles, and encourages social participation in medical transport services [2][3] Drug and Medical Device Approvals - Aied Bio received a medical device registration certificate for its gene mutation detection kit, which is now approved in China, Japan, and Europe, aiding non-small cell lung cancer patients [4] - Hainan Haiyao's subsidiary obtained a drug registration certificate for Fumaric Acid Vonoprazan Tablets, the first P-CAB for reflux esophagitis in China [5] Capital Market Activities - China National Pharmaceutical Modern signed a drug listing license transfer contract for Lactulose Oral Solution, with a total transfer fee of 5.86 million yuan, projected to generate 2.069 billion yuan in sales in 2024 [6] - Jiangsu Hengrui Medicine and Neurocrine Biosciences entered a collaboration for developing NLRP3 inhibitors, with a potential total value of $881.5 million [7][8] Industry Events - The 2025 medical insurance negotiation concluded, with results expected to be announced in early December [9] - The only approved stem cell drug in China, Aimi Maito Sai Injection, is included in the "Beijing Universal Health Insurance" with a maximum reimbursement of 65% [10] Regulatory Issues - The executive director of CSPC Pharmaceutical Group was fined 5 million yuan for insider trading related to a merger announcement [11]

Core Viewpoint - The company, Adebiotech, has recently received a medical device registration certificate from the National Medical Products Administration of China for its EGFR/ALK/ROS1/MET/KRAS gene mutation detection kit, which is significant for non-small cell lung cancer diagnostics [1] Group 1: Product Approval and Features - The product covers 11 essential and extended genes for non-small cell lung cancer, enabling both DNA and RNA testing [1] - The EGFR, ALK, ROS1, MET, and KRAS genes have been approved for companion diagnostics in China, guiding the clinical application of seven targeted therapies [1] Group 2: Market Reach and Impact - The product has been approved for sale in China, Japan, and Europe, with a total of seven genes approved for companion diagnostics [1] - It supports the clinical application of up to 22 targeted therapies, benefiting numerous non-small cell lung cancer patients globally [1]

Core Viewpoint - The company, Adicon Biological, has recently received a medical device registration certificate from the National Medical Products Administration for its product, the human EGFR/ALK/ROS1/MET/KRAS gene mutation detection kit (multiplex fluorescent PCR method) [1] Company Summary - Adicon Biological has been granted a medical device registration certificate, indicating regulatory approval for its gene mutation detection kit [1]

Core Viewpoint - The company, Aide Biology (300685.SZ), has recently received a medical device registration certificate from the National Medical Products Administration for its product, the human EGFR/ALK/ROS1/MET/KRAS gene mutation detection kit (multiplex fluorescent PCR method) [1] Group 1 - The product is designed for detecting multiple gene mutations, which is significant for personalized medicine and targeted therapies [1] - The approval from the regulatory authority indicates the product meets necessary safety and efficacy standards, potentially enhancing the company's market position [1] - This development may open new revenue streams for the company, as gene mutation testing is increasingly important in oncology [1]

Group 1 - The company,艾德生物, has recently received a medical device registration certificate from the National Medical Products Administration of China for its product named "Human EGFR/ALK/ROS1/MET/KRAS Gene Mutation Detection Kit" [1]